Liminatus Pharma Inc 's

Name: Liminatus Pharma Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

LIMN Sales vs. its Competitors Q2 2026

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

<< LIMN Stock Performance Comparisons

Liminatus Pharma Inc 's Comment on Competition and Industry Peers

The company operates in the immune-oncology treatment sector and faces competition from pharmaceutical and biotechnology firms including Amgen, AstraZeneca, Bristol-Myers Squibb (BMS), Merck, Novartis, Pfizer, Roche, and Roche's subsidiary Genentech. These competitors may also offer opportunities for combination therapies. In the area of CD47-targeting drug candidates, Magrolimab, developed by Forty Seven (acquired by Gilead Sciences), is a notable competitor currently in Phase 3 clinical trials for cancer treatment.

<< See the full list of LIMN competitors

*Market share is calculated based on total revenue.

News about Liminatus Pharma Inc Contracts

Liminatus Pharma Inc. Exploring New Frontiers with Digital Asset Investment Strategies

July 25, 2025
Liminatus Pharma Inc., a firm operating in the pharmaceutical sector, has recently announced its intention to evaluate the formation of a digital asset investment vehicle. This move comes as part of a strategic internal review aimed at diversifying the company’s treasury management and exploring additional capital strategies. The evaluation highlights the growing trend among established firms to explore opportunities in the rapidly evolving landscape of digital assets, including cryptocurrencies and tokenized securities.Currently, there is no formal entity established, and no capital has been committed to this potential initiative. This indicates that Liminatus is still in the exploratory stages of assessi...

LIMN's Stock Performance relative to its Competitors

Publicly Traded Peers of Liminatus Pharma Inc

Sources: Liminatus Pharma Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Liminatus Pharma Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.